Anyirékun Fabrice Somé

Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine

Meera Venkatesan, Nahla B. Gadalla, Kasia Stepniewska et al. · American Journal of Tropical Medicine and Hygiene · 2014 · 292 citations · Full text

Antiparasitic Agent, Malaria, Genetic Epidemiology +18

Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

Issaka Sagara, Abdoul Habib Béavogui, Issaka Zongo et al. · The Lancet · 2018 · 133 citations · Full text

Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso

Anyirékun Fabrice Somé, Thomas Bazié, Issaka Zongo et al. · Parasites & Vectors · 2018 · 105 citations · Full text

Population Pharmacokinetics and Pharmacodynamics of Piperaquine in Children With Uncomplicated Falciparum Malaria

Joel Tärning, Issaka Zongo, Anyirékun Fabrice Somé et al. · Clinical Pharmacology & Therapeutics · 2012 · 98 citations · Full text

Selection of Known <i>Plasmodium falciparum</i> Resistance-Mediating Polymorphisms by Artemether-Lumefantrine and Amodiaquine- Sulfadoxine-Pyrimethamine but Not Dihydroartemisinin- Piperaquine in Burkina Faso

Anyirékun Fabrice Somé, Yves Y. Séré, Christian Dokomajilar et al. · Antimicrobial Agents and Chemotherapy · 2010 · 98 citations · Full text

Antiparasitic Agent, Malaria, Parasite Genomics +17